AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 NOV 7 - (NewsRx.com & NewsRx.net) -- The U.S. Food and Drug Administration has designated Oncophage, a cancer vaccine candidate developed by Antigenics, Inc. (AGEN), a Fast Track Product for the treatment of renal cell carcinoma.
In the FDA's letter to Antigenics, the agency stated that it is "designating as a Fast Track development program the investigation of Autologous Tumor-Derived gp96 Heat Shock Protein-Peptide Complex (HSPPC-96, Antigenics) for its superior effect on survival as an adjunct to surgical resection of renal cell carcinoma compared with no additional postsurgical treatment."
Oncophage is a vaccine comprised of a specific class of proteins known as heat shock proteins. Heat shock proteins are isolated from each patient's cancer and contain a unique profile of signals, which are the cancer's "DNA fingerprint." These unique signals have the capacity to reprogram the immune ...
Source: HighBeam Research, FDA Fast Tracks Antigenics' Oncophage For Kidney Cancer.(Brief...